Tools / Drug approvals and letters / Drugs Metoprolol Succinate Lowers the risk of cardiovascular mortality and heart failure hospitalizations. Sold as Toprol-Xl, Kapspargo Sprinkle. Every FDA application for this active ingredient: 2 branded and 28 generic.
As of Nov 16, 2026, FDA lists 30 applications for Metoprolol Succinate (sold as Toprol-Xl, Kapspargo Sprinkle), first approved Jan 10, 1992, with 3 new uses approved and 0 published complete response letters.
First approved : Jan 10, 1992 Applications : 30 New uses approved : 3 Complete response letters : 0 Medicare spending, 2025 : $458M
Medicare Spending CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name Product Part Spending, 2025 Change Beneficiaries Metoprolol Succinate Part D $451M -1% 8,235,783 Toprol XL Part D $4.7M -6% 8,586 Kapspargo Sprinkle Part D $2.9M +10% 15,465
What Pharmacies Pay Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change METOPROLOL TARTRATE 100 MG TAB: $0.029 per unit Generic · +16% in a year METOPROLOL TARTRATE 12.5 MG TB: $2.84 per unit Generic · new this year METOPROLOL TARTRATE 25 MG TAB: $0.016 per unit Generic · -5% in a year METOPROLOL TARTRATE 37.5 MG TB: $0.076 per unit Generic · +0% in a year METOPROLOL TARTRATE 50 MG TAB: $0.020 per unit Generic · -3% in a year METOPROLOL TARTRATE 75 MG TAB: $0.154 per unit Generic · +15% in a year KAPSPARGO SPRINKLE 100 MG CAP: $2.29 per unit Brand · +4% in a year KAPSPARGO SPRINKLE 25 MG CAP: $1.89 per unit Brand · +2% in a year KAPSPARGO SPRINKLE 50 MG CAP: $1.89 per unit Brand · +2% in a year
Shortages FDA's drug shortage list, as of Nov 13, 2026 Clinical Trials 46 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all Study Phase Status Posted An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates Ulcerative Colitis, Crohn's Disease · Sanofi Phase 1 Not yet recruiting Nov 6, 2026 BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy Cardiomyopathy, Hypertrophic Obstructive · Braveheart Bio, Inc. Phase 3 Recruiting Aug 10, 2026 Predicting Response and Exposure Changes in Cirrhosis for Effectiveness Liver Cirrhosis · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Not applicable Not yet recruiting Aug 6, 2026 Comparing Two Heart Medicines for Fast, Irregular Heartbeat (Atrial Fibrillation) Atrial Fibrillation (AF), Atrial Fibrillation With Rapid Ventricular Response · Muhammad Ali Javed Phase 4 Not yet recruiting Jul 15, 2026 MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation Atrial Flutter With Rapid Ventricular Response · Wake Forest University Health Sciences Phase 3 Recruiting Jun 8, 2026 Beta-Blockers on Neoadjuvant Immunochemotherapy for Hypertensive Patients With Gastric Cancer Gastric Cancer (GC) · Nanfang Hospital, Southern Medical University — Active, not recruiting Jun 3, 2026 Dose-Response Interaction of Metoprolol and Sufentanil for Attenuating Hemodynamic Responses in Tracheal Intubation General Anesthesia; Tracheal Intubation · Fujian Provincial Hospital Phase 4 Not yet recruiting May 19, 2026 Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes · Enhanced Emirates Limited Not applicable Enrolling by invitation May 6, 2026
Applications NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history Approved Application Sponsor Supplements Marketing Jan 10, 1992 Toprol-Xl NDA 19962 · New active ingredient Melinta Therap39 Marketed Jul 31, 2006 Metoprolol Succinate ANDA 76969 Sandoz2 Discontinued May 18, 2007 Metoprolol Succinate ANDA 76640 Nesher Pharms0 Discontinued Mar 20, 2008 Metoprolol Succinate ANDA 77779 Nesher Pharms0 Discontinued May 14, 2008 Metoprolol Succinate ANDA 77176 Nesher Pharms0 Discontinued Aug 3, 2009 Metoprolol Succinate ANDA 76862 Actavis Labs Fl Inc3 Marketed Apr 15, 2010 Metoprolol Succinate ANDA 77298 Actavis Labs Fl Inc2 Discontinued Jul 22, 2010 Metoprolol Succinate ANDA 90615 Wockhardt Bio AG1 Marketed Dec 15, 2011 Metoprolol Succinate ANDA 202033 Mylan Pharms Inc4 Discontinued Aug 1, 2012 Metoprolol Succinate ANDA 90617 Dr Reddys Labs Ltd5 Marketed Aug 15, 2012 Metoprolol Succinate ANDA 78889 Reddys5 Marketed Nov 25, 2016 Metoprolol Succinate ANDA 204161 Actavis Elizabeth5 Marketed Jan 26, 2018 Kapspargo Sprinkle NDA 210428 · New dosage form Spil2 Marketed Feb 6, 2018 Metoprolol Succinate ANDA 204106 Novast Labs2 Marketed Mar 23, 2018 Metoprolol Succinate ANDA 203894 Zydus Pharms4 Marketed Oct 26, 2018 Metoprolol Succinate ANDA 207465 Cipla2 Marketed Dec 19, 2018 Metoprolol Succinate ANDA 207206 Visum Pharm2 Marketed Mar 30, 2020 Metoprolol Succinate ANDA 203699 Alicora2 Marketed Mar 31, 2020 Metoprolol Succinate ANDA 203028 Alicora2 Marketed Nov 6, 2020 Metoprolol Succinate ANDA 205541 Hetero Labs Ltd Iii2 Marketed Nov 25, 2020 Metoprolol Succinate ANDA 211143 Alkem Labs Ltd3 Marketed Feb 12, 2021 Metoprolol Succinate ANDA 213854 Yichang Humanwell2 Marketed Jan 4, 2022 Metoprolol Succinate ANDA 210597 Prinston2 Discontinued Sep 26, 2022 Metoprolol Succinate ANDA 214004 Sunshine0 Marketed Oct 18, 2022 Metoprolol Succinate ANDA 215637 Accord Hlthcare1 Discontinued Jun 12, 2023 Metoprolol Succinate ANDA 216916 Granules0 Marketed Aug 7, 2023 Metoprolol Succinate ANDA 216509 Granules0 Discontinued Aug 15, 2023 Metoprolol Succinate ANDA 209272 Lupin0 Discontinued Jul 26, 2024 Metoprolol Succinate ANDA 214110 Zhejiang Jutai Pharm0 Marketed Jun 25, 2025 Metoprolol Succinate ANDA 206980 Ipca Labs Ltd0 Marketed
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA